211 related articles for article (PubMed ID: 37448551)
1. Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis.
Zhang N; Liu C; Di W
Onco Targets Ther; 2023; 16():545-558. PubMed ID: 37448551
[TBL] [Abstract][Full Text] [Related]
2. Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease.
Bednarek A; Mykała-Cieśla J; Pogoda K; Jagiełło-Gruszfeld A; Kunkiel M; Winder M; Chudek J
J Oncol; 2020; 2020():7267083. PubMed ID: 32508921
[TBL] [Abstract][Full Text] [Related]
3. Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.
Li Y; Zhang C; Feng L; Shen Q; Liu F; Jiang X; Pang B
Front Pharmacol; 2023; 14():1195104. PubMed ID: 37383719
[TBL] [Abstract][Full Text] [Related]
4. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of renal dysfunction in 59 patients with gynecological malignant tumor during chemotherapy].
Li N; Li XP; Wang Y; Cui H; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):818-824. PubMed ID: 27916064
[No Abstract] [Full Text] [Related]
6. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.
Hirakawa H; Nakashima C; Nakamura T; Masuda M; Funakoshi T; Nakagawa S; Horimatsu T; Matsubara K; Muto M; Kimura S; Sueoka-Aragane N
J Med Case Rep; 2017 Feb; 11(1):43. PubMed ID: 28202048
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
Velenosi TJ; Urquhart BL
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
[TBL] [Abstract][Full Text] [Related]
8. [Breast Cancer - Specifics of Gynecological Care and Counseling].
Weinberger V; Zikán M
Klin Onkol; 2016; 29 Suppl 3():S7-15. PubMed ID: 28118719
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.
Moss CL; Guerrero-Urbano T; White I; Taylor B; Kristeleit R; Montes A; Fox L; Beyer K; Sztankay M; Ratti MM; Sisca ES; Derevianko A; MacLennan S; Wood N; Wintner LM; Van Hemelrijck M
Future Oncol; 2023 Mar; 19(9):663-678. PubMed ID: 37128990
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction.
Sirisabya N; Li Y; Jaishuen A; Zheng HG; Gershenson DM; Kavanagh JJ
Int J Gynecol Cancer; 2008; 18(4):648-51. PubMed ID: 17892459
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
Brennan A; Brennan D; Rees M; Hickey M
Int J Gynecol Cancer; 2021 Mar; 31(3):352-359. PubMed ID: 33127864
[TBL] [Abstract][Full Text] [Related]
14. Applications of CRISPR-Cas9 in gynecological cancer research.
Zhang W; Liu Y; Zhou X; Zhao R; Wang H
Clin Genet; 2020 Jun; 97(6):827-834. PubMed ID: 32040210
[TBL] [Abstract][Full Text] [Related]
15. Management of Patients with Renal Failure Undergoing Dialysis During
Vermandel M; Debruyne P; Beron A; Devos L; Talbot A; Legrand JF; Provôt F; Lion G
J Nucl Med; 2020 Aug; 61(8):1161-1170. PubMed ID: 31924716
[TBL] [Abstract][Full Text] [Related]
16. [Management of chemotherapy in hemodialysis patients].
Janus N; Launay-Vacher V; Deray G; Thyss A; Thariat J
Bull Cancer; 2012 Mar; 99(3):371-80. PubMed ID: 22133734
[TBL] [Abstract][Full Text] [Related]
17. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.
Korzun T; Moses AS; Diba P; Sattler AL; Olson B; Taratula OR; Pejovic T; Marks DL; Taratula O
Small; 2023 Jul; ():e2301776. PubMed ID: 37518857
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological trends and risk factors of gynecological cancers: an update.
Keyvani V; Kheradmand N; Navaei ZN; Mollazadeh S; Esmaeili SA
Med Oncol; 2023 Feb; 40(3):93. PubMed ID: 36757546
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency.
Chatelut E; Rostaing L; Gualano V; Vissac T; De Forni M; Ton-That H; Suc JM; Houin G; Canal P
Nephron; 1994; 66(2):157-61. PubMed ID: 8139735
[TBL] [Abstract][Full Text] [Related]
20. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.
Li YF; Fu S; Hu W; Liu JH; Finkel KW; Gershenson DM; Kavanagh JJ
Int J Gynecol Cancer; 2007; 17(4):739-63. PubMed ID: 17309673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
